🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine

Found 21 matching trials

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately

PHASE3

This study will assess the immunogenicity and safety of GlaxoSmithKline (GS...

Status

Completed

Location

Multiple Locations

Start Date

1999-01

Trial ID

NCT01457508

Treatments Being Tested

DTPa-HBV-IPV/Hib (Infanrix hexa™)DTPa-HBV-IPV (Infanrix penta™)Hib (Hiberix™)

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

PHASE3

This study evaluates the immunogenicity and safety of Infanrix hexa™ (DTPa-...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-04-16

Trial ID

NCT01353703

Treatments Being Tested

Infanrix hexa™

Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers

PHASE3

The primary immunogenicity objective is to assess and compare the immunogen...

Status

Completed

Location

Site 22

Start Date

2008-03

Trial ID

NCT00667602

Treatments Being Tested

MenACWY-CRM197 (two doses)MenC PCV7 DTPa-IPV-HepB-Hib MenACWY-CRM197 (one dose)

Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

PHASE2

The purpose of this booster study is to evaluate, in subjects primed in the...

Status

Completed

Location

GSK Investigational Site

Start Date

2008-02-01

Trial ID

NCT00627458

Treatments Being Tested

Infanrix Hexa

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

PHASE3

The purpose of the present study is to demonstrate that the changes in the ...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-01-05

Trial ID

NCT00808444

Treatments Being Tested

Pneumococcal conjugate vaccine GSK1024850A (different lots)Infanrix hexa Infanrix-IPV/Hib Rotarix

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants

PHASE2

This study will assess the safety, reactogenicity and immunogenicity of two...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-09-27

Trial ID

NCT01204658

Treatments Being Tested

Pneumococcal vaccine GSK 2189242A (LD formulation 1)Pneumococcal vaccine GSK 2189242A (HD formulation 2)Synflorix Prevenar 13 Infanrix Hexa (DTPa-HBV-IPV/Hib)

NeisVac-C Single Prime Study in Infants

PHASE3

The purpose of this study is to assess the feasibility of a single priming ...

Status

Completed

Location

NZOZ Vitamed

Start Date

2010-09

Trial ID

NCT01218451

Treatments Being Tested

Meningococcal group C polysaccharide conjugate vaccine Pneumococcal 13-valent conjugate vaccine Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment

PHASE4

The aim of the current study is to determine whether ibuprofen, given as im...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-11-12

Trial ID

NCT01235949

Treatments Being Tested

GSK1024850A (SynflorixTM)Infanrix hexa Infanrix-IPV/Hib Ibuprofen Paracetamol

Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa

PHASE4

The purpose of the study is to determine whether prophylactic antipyretic t...

Status

Completed

Location

Multiple Locations

Start Date

2005-05

Trial ID

NCT00294294

Treatments Being Tested

Prevenar Infanrix hexa

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

PHASE3

The purpose of this study is to evaluate the immune response, safety and re...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-09-13

Trial ID

NCT02858440

Treatments Being Tested

Infanrix-IPV/Hib

Previous Next